Navi Medical Technologies, a Melbourne-based startup, has closed a $6.8 million funding round to commercialize technology designed to safely place and monitor central lines in newborns—addressing what experts say is one of medicine's most underappreciated safety challenges.
The funding round, led by healthcare venture capital firm KP Rx with a $4 million commitment, comes after Navi received FDA 510(k) clearance last year. An expanded FDA indication approved in 2026 now covers the broadest range of neonatal and pediatric vascular access procedures, including umbilical venous catheters and all central line placements in infants.
When a catheter slips out of place in a newborn's chest, the consequences can be severe. A misplaced line meant to deliver life-saving nutrition or medication can perforate the heart or damage surrounding tissue. For decades, neonatal intensive care units across the United States have treated this as an accepted risk.
Navi's Neonav® technology combines real-time ECG-guided catheter placement with continuous surveillance for catheter migration. The approach contrasts sharply with current U.S. practice, which typically relies on repeated X-ray imaging to confirm catheter position—a reactive method that identifies problems only after they occur.
Adult patients routinely benefit from real-time ECG-guided placement, a technique that has dramatically improved safety outcomes. Neonatal clinicians, however, have largely depended on technologies never engineered for their smallest and most vulnerable patients.
"For decades, neonatal and pediatric clinicians have relied on technologies that were never designed for their smallest patients," Navi CEO Alex Newton said. "The Neonav® was built to change that."
Navi has already begun clinical evaluations at leading U.S. pediatric hospitals. The company plans to commence commercial sales in the United States this year.
KP Rx partner Hashan De Silva cited the company's "exceptional execution—from product development to FDA clearance and early engagement with leading U.S. children's hospitals."
Innovation Victoria, which continues as an existing investor, and Pacific Channel also participated in the funding round. Roughly 3.5 million babies are born in the United States annually, with a significant proportion of those in intensive care requiring central venous access.
